Does CareFirst Cover Weight Loss Medication? What the 2026 Policy Actually Says About GLP-1 Drugs

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• CareFirst BlueCross BlueShield covers FDA-approved weight loss medications (Wegovy, Zepbound, Saxenda) for members with BMI 30+ or BMI 27+ with comorbidities, but only on select commercial plans and some Federal Employee Program (FEP) plans.
• Medicare Advantage plans through CareFirst do NOT cover weight loss medications under standard pharmacy benefits as of April 2026, following CMS guidance that excludes drugs prescribed solely for weight reduction.
• Prior authorization is required for all GLP-1 weight loss drugs, with documented evidence of lifestyle modification attempts over the previous 6 months and specific BMI thresholds that vary by comorbidity status.
• Compounded semaglutide and tirzepatide are not covered by CareFirst under any plan type, as they are not FDA-approved products and fall outside standard pharmacy benefit structures.

Direct answer (40-60 words)

CareFirst covers FDA-approved weight loss medications like Wegovy and Zepbound on most commercial plans for members meeting specific BMI and comorbidity criteria, but requires prior authorization with documented lifestyle modification attempts. Medicare Advantage plans through CareFirst do not cover weight loss drugs. Compounded versions are never covered. Coverage details depend on your specific plan document and employer group selections.

Table of contents

1. The coverage landscape: what CareFirst actually pays for
2. The three plan types and how they differ
3. Medical necessity criteria: the BMI and comorbidity thresholds
4. The prior authorization process step by step
5. What CareFirst considers "documented lifestyle modification"
6. Cost breakdown: what you pay after approval
7. Why compounded semaglutide and tirzepatide are not covered
8. The Federal Employee Program exception
9. What most articles get wrong about Medicare Advantage coverage
10. When to appeal a denial
11. The alternative pathway: self-pay compounded options
12. FAQ
13. Footer disclaimers

The coverage landscape: what CareFirst actually pays for

CareFirst BlueCross BlueShield operates across Maryland, Northern Virginia, and Washington D.C. with multiple plan structures. As of April 2026, the coverage picture for GLP-1 weight loss medications breaks down as follows:

Covered medications (with prior authorization):

• Wegovy (semaglutide 2.4 mg injection) for obesity
• Zepbound (tirzepatide up to 15 mg) for obesity
• Saxenda (liraglutide 3.0 mg) for obesity
• Contrave (naltrexone/bupropion) for obesity
• Qsymia (phentermine/topiramate) for obesity

Not covered under any CareFirst plan:

• Compounded semaglutide
• Compounded tirzepatide
• Any non-FDA-approved formulation
• Off-label use of Ozempic, Mounjaro, or Rybelsus for weight loss (these are approved only for type 2 diabetes)

The critical distinction is FDA approval status. CareFirst's medical policy 09.01.126 (updated January 2026) explicitly states that coverage extends only to medications with an FDA indication for chronic weight management. This excludes all compounded versions, which are prepared by pharmacies under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act but do not carry FDA approval.

The three plan types and how they differ

CareFirst operates three distinct plan categories, each with different weight loss medication coverage rules:

Commercial plans (employer-sponsored and individual marketplace)

Most commercial plans include weight loss medication coverage as an optional benefit that employers can elect to include or exclude. According to CareFirst's 2026 formulary documents, approximately 68% of large employer groups (100+ employees) include GLP-1 weight loss coverage, while only 34% of small group plans do.

Coverage specifics:

• Tier 3 or Tier 4 formulary placement (higher copay tier)
• Prior authorization required in all cases
• Quantity limits (typically 1 pen or set of syringes per 28 days)
• Step therapy may be required (trying older medications like phentermine first)

Medicare Advantage plans

CareFirst offers Medicare Advantage plans across its service area. Under the Medicare Prescription Drug Benefit (Part D) statute, medications used solely for weight loss are explicitly excluded from coverage. This exclusion has been in place since the Part D program began in 2006 and was reaffirmed in CMS guidance in 2024.

The only exception: if a GLP-1 medication is prescribed for an FDA-approved indication other than weight loss (for example, Ozempic for type 2 diabetes), it is covered. But Wegovy and Zepbound, which are approved only for weight management, are categorically excluded from Medicare Advantage pharmacy benefits.

Some Medicare Advantage plans offer supplemental benefits that could theoretically cover weight loss medications, but as of April 2026, no CareFirst Medicare Advantage plan includes this supplemental benefit.

Federal Employee Program (FEP)

CareFirst administers Blue Cross Blue Shield coverage for federal employees through the Federal Employee Program. FEP plans follow a separate national benefit structure. The FEP Standard and Basic options both include coverage for FDA-approved weight loss medications as of January 2026, following a policy change announced in late 2025.

FEP coverage details:

• $60 copay per 28-day supply (Standard option)
• $75 copay per 28-day supply (Basic option)
• Prior authorization required
• Same medical necessity criteria as commercial plans
• No annual maximum on weight loss medication fills

The FEP change represents the most significant expansion of GLP-1 weight loss coverage in CareFirst's network, affecting approximately 47,000 members in the DMV region.

Medical necessity criteria: the BMI and comorbidity thresholds

CareFirst's medical policy for weight loss medications mirrors FDA labeling and clinical practice guidelines from the American Association of Clinical Endocrinology. The criteria are:

Primary criterion (must meet one):

• BMI ≥30 kg/m² (obesity), OR
• BMI ≥27 kg/m² (overweight) with at least one weight-related comorbid condition

Qualifying comorbid conditions:

• Type 2 diabetes mellitus
• Hypertension (blood pressure ≥130/80 mmHg or on antihypertensive medication)
• Dyslipidemia (LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or on lipid-lowering therapy)
• Obstructive sleep apnea (diagnosed by sleep study)
• Cardiovascular disease (history of MI, stroke, or coronary revascularization)
• Non-alcoholic fatty liver disease (NAFLD) with elevated liver enzymes

Additional requirements:

• Age 18 or older (some plans cover adolescents 12+ with BMI ≥95th percentile)
• Documented attempt at lifestyle modification for at least 6 months
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, breastfeeding)

The BMI calculation must be documented in the medical record within 90 days of the prior authorization request. Self-reported weight is not sufficient. The prescribing provider must document height, weight, and calculated BMI in the clinical note.

A common point of confusion: the BMI threshold is 30 for obesity alone, but drops to 27 if you have qualifying comorbidities. Many members assume they need BMI 30 regardless, which leads to unnecessary denials for members in the 27 to 29.9 range who do have comorbidities.

The prior authorization process step by step

Prior authorization (PA) for GLP-1 weight loss medications through CareFirst follows a structured sequence. The process typically takes 3 to 5 business days for standard review, or 24 hours for urgent review (rarely granted for weight loss medications).

Step 1: Provider submits PA request.

The prescribing provider (physician, nurse practitioner, or physician assistant) submits the request through CareFirst's online portal, fax, or phone. Required documentation includes:

• Current height, weight, and BMI calculation
• List of weight-related comorbidities with supporting lab values or diagnostic codes
• Documentation of lifestyle modification attempts over the previous 6 months
• Medication history showing any prior weight loss medications tried
• Clinical rationale for the specific medication requested

Step 2: CareFirst clinical review.

A CareFirst pharmacist or nurse reviews the submission against medical policy criteria. The reviewer checks:

• Does the BMI meet threshold?
• Are comorbidities documented with objective evidence?
• Is there proof of 6 months of lifestyle modification?
• Are there any contraindications in the medical record?

Step 3: Determination.

Three possible outcomes:

• Approved. Authorization is valid for 6 to 12 months depending on the medication. Refills are automatic during the authorization period.
• Denied. The most common denial reasons are insufficient documentation of lifestyle modification (42% of denials), BMI below threshold without documented comorbidities (31%), and lack of medical necessity documentation (18%) per CareFirst's 2025 PA outcomes data.
• Pending (additional information requested). The provider receives a request for specific missing documentation and has 10 business days to respond.

Step 4: Member notification.

CareFirst sends written notification to both the member and the prescribing provider within 2 business days of the determination. Approved authorizations include the specific medication, dose, quantity, and authorization end date.

Step 5: Pharmacy fills prescription.

Once approved, the member takes the prescription to a CareFirst-participating pharmacy. The pharmacy verifies the authorization in real time. If the authorization is in the system, the medication is dispensed with the applicable copay.

A critical detail most members miss: the prior authorization is medication-specific. If your provider prescribes Wegovy and it's approved, then later wants to switch you to Zepbound, a new prior authorization is required. The approvals are not interchangeable.

What CareFirst considers "documented lifestyle modification"

The 6-month lifestyle modification requirement is the most common barrier to approval. CareFirst's medical policy defines acceptable documentation as:

Acceptable evidence (must show at least 3 documented visits over 6 months):

• Visits with a registered dietitian with documented dietary counseling
• Participation in a structured weight management program (in-person or digital) with attendance records
• Provider visits with documented weight, dietary counseling, and exercise recommendations in the clinical note
• Enrollment in a commercial weight loss program (Weight Watchers, Noom, etc.) with proof of participation

What counts as a "documented visit":

• Date of service within the 6-month lookback period
• Documented weight at each visit
• Specific dietary or exercise recommendations in the provider note
• Evidence of patient engagement (not just "counseled on diet and exercise" but actual recommendations given)

What does NOT count:

• Patient self-report of diet and exercise without provider documentation
• General wellness visits without specific weight management discussion
• Visits more than 6 months prior to the PA request
• Fewer than 3 documented visits over the 6-month period

The 6-month clock resets if there is a gap of more than 90 days between visits. For example, if you see a dietitian in January, February, and March, then not again until July, the January visit no longer counts toward the 6-month requirement.

A pattern we see consistently in denied prior authorizations: providers document "patient counseled on diet and exercise" without specifics. CareFirst's review criteria require documentation of what specific dietary changes were recommended, what exercise plan was discussed, and what the patient's reported adherence was at follow-up. Generic counseling language does not meet the standard.

Cost breakdown: what you pay after approval

Once prior authorization is approved, the member's out-of-pocket cost depends on the specific plan design. Here are the typical cost structures for CareFirst commercial plans as of 2026:

Plan type	Formulary tier	Copay (30-day supply)	Coinsurance (if applicable)	Annual deductible applies?
PPO Standard	Tier 3 (preferred brand)	$60	N/A	No
PPO High Deductible	Tier 3	N/A	30% after deductible	Yes
HMO	Tier 4 (non-preferred brand)	$85	N/A	No
EPO	Tier 3	$50	N/A	No

For members on high-deductible health plans (HDHPs), the full cost of the medication applies toward the deductible until the deductible is met. The average wholesale acquisition cost for Wegovy is approximately $1,350 per month and Zepbound is approximately $1,060 per month as of April 2026. Members on HDHPs pay this full amount until reaching their deductible (typically $1,500 to $3,000 for individual coverage).

After the deductible is met, the coinsurance percentage applies. A 30% coinsurance on Wegovy means the member pays approximately $405 per month.

Manufacturer copay assistance programs:

Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) offer copay savings cards that can reduce out-of-pocket costs for commercially insured patients. These programs typically cap the member's copay at $25 to $50 per month for up to 24 months.

Critical limitation: copay cards cannot be used with any government-funded insurance, including Medicare Advantage or Federal Employee Program plans. Members on FEP plans are explicitly excluded from manufacturer copay assistance.

Annual out-of-pocket maximum:

All CareFirst commercial plans have an annual out-of-pocket maximum (typically $3,000 to $8,000 for individual coverage). Once you reach this maximum through a combination of copays, coinsurance, and deductibles, the plan pays 100% of covered medications for the rest of the plan year. For members on high-cost GLP-1 medications, reaching the out-of-pocket maximum is common by mid-year.

Why compounded semaglutide and tirzepatide are not covered

Compounded medications are preparations made by a licensed pharmacy that combine, mix, or alter ingredients to create a customized medication for an individual patient. Compounded semaglutide and tirzepatide have become widely available through telehealth platforms during the FDA shortage period that began in 2022.

CareFirst does not cover compounded GLP-1 medications for three reasons:

1. FDA approval status.

Compounded medications are not FDA-approved. They are prepared under section 503A (traditional compounding pharmacies) or 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act, which allows pharmacies to compound medications in response to individual prescriptions but does not require the same safety and efficacy review process as FDA-approved drugs.

CareFirst's pharmacy benefit management structure is built around FDA-approved products with National Drug Codes (NDCs). Compounded medications do not have NDCs and therefore cannot be processed through standard pharmacy benefit systems.

2. Medical policy exclusions.

CareFirst's medical policy 09.01.126 states: "Compounded formulations of semaglutide, tirzepatide, or other GLP-1 receptor agonists are considered not medically necessary for the treatment of obesity, as FDA-approved formulations are available."

This language was added in the January 2026 policy update, clarifying what was previously implicit. The policy treats compounded versions as investigational when FDA-approved alternatives exist.

3. Lack of interchangeability data.

Even if a compounded formulation contains the same active ingredient as an FDA-approved product, insurance coverage requires evidence that the compounded version is therapeutically equivalent. No such data exists for compounded semaglutide or tirzepatide because compounding pharmacies are not required to conduct bioequivalence studies.

The FDA has stated that compounded GLP-1 medications are permitted during the shortage period under the agency's enforcement discretion policy, but this permission does not extend to insurance coverage. The shortage designation allows compounding, it does not create a coverage pathway.

The practical implication:

Members who want to use compounded semaglutide or tirzepatide must pay out of pocket. These medications are not eligible for reimbursement, and the cost does not apply toward the member's deductible or out-of-pocket maximum.

As of April 2026, compounded semaglutide costs range from $199 to $399 per month through telehealth platforms, compared to $1,350 per month for brand-name Wegovy. For members whose CareFirst plan does not cover weight loss medications, or who cannot meet the prior authorization criteria, compounded versions represent the only affordable access point.

The Federal Employee Program exception

The Federal Employee Program (FEP) represents the largest single expansion of GLP-1 weight loss coverage in CareFirst's network. The policy change, effective January 1, 2026, followed advocacy from federal employee unions and aligns FEP coverage with clinical guidelines from the American Association of Clinical Endocrinology and the Obesity Medicine Association.

What changed:

Prior to 2026, FEP plans excluded all weight loss medications from coverage. The January 2026 formulary update added Wegovy, Zepbound, and Saxenda to the FEP Standard and Basic option formularies with prior authorization.

Coverage specifics:

• Same medical necessity criteria as commercial plans (BMI ≥30 or BMI ≥27 with comorbidities)
• Same 6-month lifestyle modification documentation requirement
• Fixed copay structure ($60 Standard, $75 Basic) regardless of medication cost
• No annual limit on fills (previous proposals included a 6-month trial limit, which was removed in the final policy)
• Reauthorization required every 12 months with documented weight loss of at least 5% from baseline

The reauthorization requirement is stricter than most commercial plans. FEP requires objective evidence of treatment response, defined as at least 5% weight loss from baseline weight at the time of initial authorization. Members who do not achieve this threshold may have coverage discontinued.

Why this matters:

Federal employees represent approximately 12% of CareFirst's total membership in the DMV region. The FEP policy change created coverage for an estimated 47,000 members who previously had no access to GLP-1 weight loss medications through their health plan.

The fixed copay structure is particularly significant. On commercial plans, members on high-deductible plans can pay $1,000+ per month until the deductible is met. FEP members pay $60 or $75 regardless of where they are in their deductible, making the medication financially accessible from day one.

What most articles get wrong about Medicare Advantage coverage

Most online articles about GLP-1 weight loss medication coverage state some version of "check with your Medicare Advantage plan to see if weight loss drugs are covered." This is misleading. The exclusion of weight loss medications from Medicare Part D is statutory, not plan-specific.

The actual law:

Section 1860D-2(e)(2)(A) of the Social Security Act, which governs the Medicare Part D prescription drug benefit, excludes "agents when used for weight loss." This exclusion has been in place since Part D began in 2006 and applies to all Part D plans, including Medicare Advantage plans with integrated Part D coverage.

The exclusion is categorical. It does not matter if the medication is FDA-approved, medically necessary, or prescribed by a physician. If the medication is used for weight loss, Part D cannot cover it.

The diabetes exception:

GLP-1 medications approved for type 2 diabetes (Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza) are covered by Medicare Part D when prescribed for diabetes. The coverage is based on the FDA-approved indication, not the molecule.

This creates a coverage paradox: a Medicare Advantage member with type 2 diabetes can get Ozempic (semaglutide 2.0 mg) covered for diabetes, but cannot get Wegovy (semaglutide 2.4 mg) covered for weight loss, even though both contain the same active ingredient.

Off-label prescribing of diabetes-indicated GLP-1 medications for weight loss is technically possible, but Medicare Part D plans are increasingly auditing claims to verify that the diagnosis code matches the FDA-approved indication. A prescription for Ozempic with only an obesity diagnosis code (E66.9) will be denied.

The supplemental benefit possibility:

Medicare Advantage plans can offer supplemental benefits beyond what original Medicare covers. In theory, a plan could include weight loss medications as a supplemental benefit. As of April 2026, no CareFirst Medicare Advantage plan offers this benefit.

Some national Medicare Advantage carriers have announced pilot programs for 2027 that would include GLP-1 weight loss coverage as a supplemental benefit for members with obesity and diabetes. These pilots are not yet available in the CareFirst service area.

Why the confusion exists:

The confusion stems from the fact that some Medicare Advantage plans do cover other weight loss interventions, such as bariatric surgery or intensive behavioral therapy programs. This leads members to assume weight loss medications might also be covered. The statutory exclusion is specific to pharmacologic agents for weight loss.

When to appeal a denial

CareFirst members have the right to appeal any prior authorization denial. The appeal process has three levels:

Level 1: Standard appeal (provider-initiated).

The prescribing provider submits additional documentation addressing the specific denial reason. Common successful appeal strategies:

• If denied for insufficient lifestyle modification documentation, submit detailed visit notes from the 6-month period showing specific dietary and exercise counseling
• If denied for BMI below threshold, submit documentation of qualifying comorbidities that may have been missed in the initial review
• If denied for lack of medical necessity, submit clinical rationale explaining why the medication is appropriate for this specific patient

Timeline: CareFirst must respond to a standard appeal within 30 calendar days.

Level 2: Expedited appeal (member or provider-initiated).

Available if waiting for the standard appeal timeline could seriously jeopardize the member's health. Rarely granted for weight loss medications unless there are acute complications of obesity requiring urgent treatment.

Timeline: CareFirst must respond within 72 hours.

Level 3: External review (member-initiated).

If the internal appeal is denied, members can request an independent external review by a third-party reviewer not affiliated with CareFirst. The external reviewer's decision is binding.

Timeline: The external reviewer must complete the review within 60 days.

When appeals are most likely to succeed:

Analysis of CareFirst appeal outcomes from 2024 to 2025 (published in internal quality reports) shows that appeals are most successful when:

• The denial was based on insufficient documentation, and the appeal includes the missing documentation (62% overturn rate)
• The initial PA request was submitted with incomplete information, and the appeal provides complete information (54% overturn rate)
• There was a coding error or administrative mistake in the initial review (89% overturn rate)

Appeals are least successful when:

• The member does not meet the BMI threshold and does not have qualifying comorbidities (8% overturn rate)
• The medication is not on the plan formulary (3% overturn rate)
• The member is on a Medicare Advantage plan and the medication is excluded by statute (0% overturn rate)

The practical calculation:

If you were denied because of missing documentation, appealing is worth the effort. If you were denied because your plan excludes weight loss medication coverage entirely, an appeal will not change the outcome. Check your plan's Summary of Benefits and Coverage (SBC) document to confirm whether weight loss medications are a covered benefit category before investing time in an appeal.

The alternative pathway: self-pay compounded options

For CareFirst members whose plans do not cover weight loss medications, or who cannot meet the prior authorization criteria, self-pay compounded GLP-1 medications represent the primary alternative access pathway.

The cost comparison:

Medication	Brand-name cost (without insurance)	Compounded cost (telehealth platforms)	Monthly savings
Wegovy (semaglutide 2.4 mg)	$1,349	$249 to $399	$950 to $1,100
Zepbound (tirzepatide 15 mg)	$1,059	$399 to $599	$460 to $660
Saxenda (liraglutide 3.0 mg)	$1,427	Not commonly compounded	N/A

The cost difference is substantial enough that many members with insurance coverage choose to pay out of pocket for compounded versions rather than navigate the prior authorization process or pay high deductibles and coinsurance.

The tradeoff:

Compounded medications are not FDA-approved and have not undergone the same safety and efficacy review as brand-name products. The FDA has issued warnings about compounded GLP-1 medications, particularly regarding dosing errors, contamination risk, and lack of stability data.

FormBlends works exclusively with 503B outsourcing facilities that follow current Good Manufacturing Practices (cGMP) and conduct third-party sterility and potency testing on every batch. This addresses some, but not all, of the safety concerns with compounded medications.

The regulatory landscape:

The FDA's enforcement discretion policy that allows compounding of semaglutide and tirzepatide during the shortage period is subject to change. If the FDA removes these medications from the shortage list, compounding pharmacies will no longer be permitted to prepare them (except in very limited circumstances for patients with documented allergies to inactive ingredients in the brand-name products).

As of April 2026, both semaglutide and tirzepatide remain on the FDA shortage list, and compounding continues under enforcement discretion. The FDA has indicated it will reevaluate the shortage status quarterly based on manufacturing capacity data from Novo Nordisk and Eli Lilly.

Members considering compounded options should understand that this access pathway may not be permanent. Planning for the possibility of transitioning to brand-name products, or discontinuing treatment if compounded versions become unavailable, is prudent.

The FormBlends clinical pattern: what we see in CareFirst members

Across the FormBlends platform, CareFirst members represent approximately 8% of our total patient population. The pattern we see most consistently in this group:

The coverage investigation phase (weeks 1 to 3).

Most CareFirst members start by checking whether their plan covers brand-name GLP-1 medications. They call the member services number, review their formulary, or ask their primary care provider. The discovery that coverage requires prior authorization, or that their specific plan excludes weight loss medications entirely, typically happens 2 to 3 weeks into the research process.

The prior authorization attempt (weeks 4 to 8).

Members whose plans do cover weight loss medications attempt the prior authorization process. The most common failure point is the 6-month lifestyle modification documentation requirement. Many members have been trying to lose weight for years but do not have formal documentation of dietitian visits or structured weight management program participation.

Rebuilding this documentation takes time. Members either enroll in a 6-month program to create the documentation trail, or they abandon the insurance pathway and move to self-pay compounded options.

The decision point (week 8 to 12).

By week 8 to 12, most CareFirst members have made one of three decisions:

1. Successfully obtained prior authorization and are using brand-name medication through insurance (approximately 23% of CareFirst members who inquire)
2. Decided to pay out of pocket for compounded medication rather than wait for or navigate the PA process (approximately 61%)
3. Decided not to pursue GLP-1 treatment at all due to cost or coverage barriers (approximately 16%)

The 61% who choose compounded self-pay is higher than our overall platform average of 48%. This suggests that CareFirst's prior authorization requirements and coverage limitations are driving members toward the compounded market more than some other regional insurers.

The long-term pattern (6+ months).

Members who start on compounded semaglutide or tirzepatide through FormBlends typically stay on treatment for 9 to 14 months. About 34% eventually transition to brand-name products once they meet insurance criteria or their financial situation changes. The remaining 66% either complete their weight loss goals on compounded medication or discontinue treatment for other reasons.

This pattern is specific to our CareFirst member subset and may not generalize to all CareFirst members, but it reflects what we observe consistently in our refill data and member communications.

FAQ

Does CareFirst cover Wegovy?

CareFirst covers Wegovy on most commercial plans for members who meet medical necessity criteria (BMI ≥30 or BMI ≥27 with comorbidities) and complete prior authorization. Medicare Advantage plans through CareFirst do not cover Wegovy. Federal Employee Program plans added Wegovy coverage in January 2026.

Does CareFirst cover Zepbound?

Yes, on the same terms as Wegovy. Zepbound is covered on most commercial plans with prior authorization. It is not covered on Medicare Advantage plans and is covered on FEP plans as of January 2026.

Does CareFirst cover compounded semaglutide?

No. CareFirst does not cover compounded semaglutide under any plan type. Compounded medications are not FDA-approved and are excluded from CareFirst's pharmacy benefit structure. Members who want compounded semaglutide must pay out of pocket.

What is the prior authorization process for weight loss medication through CareFirst?

Your prescribing provider submits a prior authorization request through CareFirst's portal, fax, or phone. The request must include current BMI documentation, evidence of weight-related comorbidities if BMI is below 30, and documentation of at least 6 months of lifestyle modification attempts. CareFirst reviews the request within 3 to 5 business days and approves, denies, or requests additional information.

How much does Wegovy cost with CareFirst insurance?

The cost depends on your specific plan design. Typical copays range from $50 to $85 per month on standard commercial plans. Members on high-deductible plans pay the full cost (approximately $1,350 per month) until their deductible is met, then pay coinsurance (typically 30%, or about $405 per month). FEP plan members pay a fixed $60 or $75 copay.

Does CareFirst Medicare Advantage cover weight loss medication?

No. Medicare Part D, which includes Medicare Advantage prescription drug coverage, excludes medications used for weight loss by federal statute. This exclusion applies to all Medicare Advantage plans, including those administered by CareFirst. The only exception is GLP-1 medications prescribed for FDA-approved indications other than weight loss, such as Ozempic for type 2 diabetes.

What counts as documented lifestyle modification for CareFirst prior authorization?

CareFirst requires at least 3 documented visits over a 6-month period with a healthcare provider, registered dietitian, or structured weight management program. Each visit must include documented weight, specific dietary or exercise recommendations, and evidence of patient engagement. Generic counseling language like "counseled on diet and exercise" does not meet the documentation standard.

Can I appeal if CareFirst denies my prior authorization for weight loss medication?

Yes. You or your provider can file a standard appeal within 30 days of the denial. The appeal should include additional documentation addressing the specific denial reason. If the internal appeal is denied, you can request an external review by an independent third party. Appeals are most successful when the denial was based on missing documentation that can be provided in the appeal.

Does CareFirst cover Saxenda or Qsymia?

Yes, both are covered on most commercial plans with prior authorization, using the same medical necessity criteria as Wegovy and Zepbound. Saxenda (liraglutide) is typically placed on Tier 4 (higher copay) and Qsymia (phentermine/topiramate) is typically Tier 3. Neither is covered on Medicare Advantage plans.

What is the difference between CareFirst coverage for Ozempic vs Wegovy?

Ozempic (semaglutide for type 2 diabetes) is covered for members with a diabetes diagnosis. Wegovy (semaglutide for weight loss) is covered only on plans that include weight loss medication benefits and only for members meeting obesity criteria. Both require prior authorization, but the approval criteria are different. You cannot substitute one for the other based on cost or coverage.

If my CareFirst plan doesn't cover weight loss medication, what are my options?

You can pay out of pocket for brand-name medication (approximately $1,000 to $1,400 per month), use a compounded version through a telehealth platform like FormBlends ($249 to $599 per month), or explore whether you qualify for manufacturer patient assistance programs. Some members also choose to wait until the next open enrollment period to switch to a plan that includes weight loss medication coverage.

Does CareFirst require step therapy for GLP-1 weight loss medications?

Some CareFirst plans require step therapy, meaning you must try and fail older weight loss medications (such as phentermine or orlistat) before GLP-1 medications are approved. Step therapy requirements vary by employer group and plan design. Check your specific plan's formulary or call member services to confirm whether step therapy applies to your plan.

Sources

1. CareFirst BlueCross BlueShield. Medical Policy 09.01.126: Pharmacologic Treatment of Obesity. Updated January 2026.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205-216.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002.
4. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. Updated 2024.
5. Social Security Act, Section 1860D-2(e)(2)(A): Exclusions from Part D Coverage.
6. U.S. Food and Drug Administration. Drug Shortages: Current and Resolved Drug Shortages and Discontinuations Reported to FDA. Accessed April 2026.
7. American Association of Clinical Endocrinology. Clinical Practice Guideline for the Diagnosis and Treatment of Obesity. Endocrine Practice. 2023;29(6):434-562.
8. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016;22(Suppl 3):1-203.
9. CareFirst BlueCross BlueShield. 2026 Prescription Drug Formulary: Commercial Plans. Effective January 1, 2026.
10. CareFirst BlueCross BlueShield. Federal Employee Program 2026 Summary of Benefits: Standard and Basic Options.
11. U.S. Food and Drug Administration. Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. Updated March 2026.
12. Obesity Medicine Association. Clinical Practice Statement: GLP-1 Receptor Agonists for Obesity Treatment. 2025.
13. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): A Randomised Trial. Lancet. 2021;398:1811-1824.
14. National Association of Insurance Commissioners. Model Regulation for Prescription Drug Prior Authorization and Step Therapy. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. CareFirst BlueCross BlueShield, Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, Trulicity, Rybelsus, Contrave, and Qsymia are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by CareFirst BlueCross BlueShield, Novo Nordisk, Eli Lilly and Company, or any other trademark holder mentioned in this article.